Compare GE HealthCare Technologies Inc. Common Stock (GEHC) vs Marqeta Inc (MQ) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
GE HealthCare Technologies Inc. Common Stock vs Marqeta Inc — how do they compare? GE HealthCare Technologies Inc. Common Stock trades at $68.6 (market cap $30.93B), while Marqeta Inc trades at $18.39 (market cap $1.89B). The key difference: GE HealthCare Technologies Inc. Common Stock is far larger — about 16.4× Marqeta Inc's market cap, and GE HealthCare Technologies Inc. Common Stock pays a 0.23% dividend while Marqeta Inc pays none. Which is the better fit depends on your goals.
| GEHC | MQ | |
|---|---|---|
Market Cap | $30.93B | $1.89B |
Volume | 5,033,451 | 809,068 |
Sector | Health | Technology |
52-Week High | $88.16 | $20.32 |
52-Week Low | $59.48 | $15.04 |
Enterprise Value | $39.39B | $1.21B |
Dividend Yield | 0.23% | — |
Typical Hold Time | — | 44 Days |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
GE HealthCare (GEHC) trades at $68.79, up 1.55% today, with a neutral technical signal. The company reported mixed quarterly earnings, beating in Q2 2026 but missing in Q1, and is set to announce Q3 results on October 28, 2026. Recent developments include a $945 million acquisition of SOFIE Biosciences to expand its PET radiopharmaceutical footprint, alongside ongoing securities fraud investigations noted in recent news.
The outlook is cautiously optimistic, supported by a strong analyst consensus with a $79.64 price target and no sell ratings. Key opportunities include growth from strategic acquisitions and AI innovations, while risks involve legal investigations, integration challenges from the SOFIE deal, and potential margin pressures from increased investing cash outflows in 2026.
Marqeta (MQ) trades at $18.56, up 1.48% today, with a bullish technical signal from moving averages but overbought RSI levels. The company reported three consecutive quarterly EPS beats, with Q3 2026 results expected soon. Revenue has recovered from $507M in 2024 to $625M in 2025, though net income remains negative. Positive cash flow trends emerged in 2025, with net cash flow turning positive at $86M.
The outlook is mixed: strong operational momentum and partnerships (e.g., with Google and BVNK) support growth, but high valuation ratios (P/E 206.22) and thin net margins (1.53%) pose risks. Analyst consensus is cautious with a $11.38 price target, implying downside, yet institutional sentiment is divided amid earnings improvements.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
No sentiment data available yet.
About GE HealthCare Technologies Inc. Common Stock
GE HealthCare Technologies Inc. is a medical technology company, spun off from General Electric in 2023, that develops imaging systems, ultrasound devices, patient monitoring equipment, and diagnostic imaging agents. Its product lines include CT, MRI, and mammography systems alongside anesthesia delivery and maternal-infant care solutions.
Read more on GEHC →About Marqeta Inc
Headquartered in Oakland, California, and founded in 2010, Marqeta provides its clients with a card-issuing platform that offers the infrastructure and tools necessary to offer digital, physical, and tokenized payment options without the need for a traditional bank. The company's open APIs are designed to allow third parties like DoorDash, Klarna, and Block to rapidly develop and deploy innovative card-based products and payment services without the need to develop the underlying technology. The company generates revenue primarily through processing and ATM fees for cards issued on its platform.
Read more on MQ →
